Company Name: Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The company uses its proprietary ProCellEx® plant cell-based protein expression system to develop recombinant therapeutic proteins. The company’s first commercial product is a long-term enzyme replacement therapy for adult patients with a confirmed diagnosis of Type 1 Gaucher disease.
Ticker Symbol: PLX (AMEX)
Company Website: www.protalix.com
Social Media: Protalix BioTherapeutics LinkedIn
Headquarters: Carmiel, Israel